+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Myasthenia Gravis Therapeutics Market - Growth, Trends, and Forecasts (2020 - 2025)

  • PDF Icon


  • 111 Pages
  • June 2020
  • Region: Global
  • Mordor Intelligence
  • ID: 4896207
Myasthenia gravis (MG) is a long-term neuromuscular disease that leads to varying degrees of skeletal muscle weakness. Muscles of the eyes, face, and swallowing are the most commonly affected muscles in the body. The weakening of these muscles can result in double vision, drooping eyelids, trouble talking, and trouble walking. Although a rare disease, the prevalence of the disease has increased over the past few decades, as per National Organization for Rare Disorders. As a result, the research and development in understanding the disease and finding a cure have also increased. these factors have helped this market grow.

However, the cost of treatment still remains high for the disease. This has been restraining the market growth.

Key Market Trends

Medications are Expected to Cover a Large Share of the Market

There are two primary therapies for the treatment of Myasthenia Gravis. Symptomatic treatment (acetylcholinesterase inhibition) is used to increase the amount of acetylcholine (ACh) available at the neuromuscular junction and Chronic immunosuppressive therapies (glucocorticoids and nonsteroidal immunosuppressive agents) are used to target the underlying immune dysregulation are the two primary therapies.

Acetylcholine esterase (AChE) inhibitors are considered to be the basic treatment of myasthenia gravis (MG). Edrophonium is primarily used as a diagnostic tool owing to its short half-life. Pyridostigmine is used for long-term maintenance. Moreover, research and development are being done to further improve the efficacy of these medications

North America is Expected to Dominate the Myasthenia Gravis Market

According to Myasthenia Gravis Foundation Of America 2019 data, the prevalence of myasthenia gravis in the United States is estimated at 14 to 20 per 100,000 population, which approximately translates to 36,000 to 60,000 cases in the United States. However, the report states that myasthenia gravis may be underdiagnosed in many cases and the prevalence might be higher. Report also suggests that women are more often affected than men. The most common age at onset is the 20s and 30s in women and the 60s and 70s in men.

However, the developed North American countries like the US and Canada have well structured and development healthcare systems. These countries also promote research and development for rare diseases and hence have very high expenditure on healthcare. As a result of these policies, many companies globally are encouraged to operate in this region.

Moreover, most of the population in developed countries like the US and Canada are covered under medical and health insurance and hence, are able to afford the expensive medication and therapies for myasthenia gravis. Hence, the North American region is expected to cover a large share of the myasthenia gravis market.

Competitive Landscape

Majority of the myasthenia gravis therapeutics are being manufactured by the global key players. Market leaders with more funds for research and better distribution system have established their position in the market. Moreover, Asia-pacific is witnessing an emergence of some small players due to the rise of awareness and this has also helped the market grow.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

This product will be delivered within 2 business days.

Table of Contents

1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Incidence of Myasthenia Gravis
4.2.2 Increasing Research and Development for Myasthenia Gravis
4.3 Market Restraints
4.3.1 High Cost of Treatment
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5.1 By Treatment
5.1.1 Medication
5.1.2 Surgery
5.1.3 Others
5.2 By End-User
5.2.1 Hospitals
5.2.2 Clinics
5.2.3 Others
5.3 Geography
5.3.1 North America United States Canada Mexico
5.3.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.3.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.3.4 Middle-East and Africa GCC South Africa Rest of Middle-East and Africa
5.3.5 South America Brazil Argentina Rest of South America
6.1 Company Profiles
6.1.1 Alexion Pharmaceutical Inc.
6.1.2 Argenx
6.1.3 Astellas Pharma
6.1.4 CuraVac
6.1.5 Grifols SA
6.1.6 Immunovant
6.1.7 Mitsubishi Tanabe Pharma
6.1.8 Novartis
6.1.9 UCB Pharma
6.1.10 Bausch Health

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Alexion Pharmaceutical Inc.
  • Argenx
  • Astellas Pharma
  • CuraVac
  • Grifols SA
  • Immunovant
  • Mitsubishi Tanabe Pharma
  • Novartis
  • UCB Pharma
  • Bausch Health